Key Highlights
- Shares fell 0.98% to USD 60.82 on relative Volume of 1.95.
- Third-quarter revenues were USD 1.02 billion, with a net loss of USD 122.8 million.
- Acquired in-process Research and Development expense was USD 287.7 million.
- 2026 Revenue guidance was updated to USD 3.8 billion to USD 3.9 billion.
BioMarin (NASDAQ:BMRN) shares traded at USD 60.82 on November 20, 2026, down 0.98%, with a relative volume at time of 1.95. The company has given no reason for the heavy trading. Its Earnings Call took place on November 2, its report for the quarter ended September 30, 2026 was filed on November 3, and in November it announced a regulatory date for VOXZOGO, all before the session.
BioMarin is a Delaware corporation based at 770 Lindaro Street in San Rafael, California. It develops and commercializes rare disease therapies, with marketed products including VOXZOGO, VIMIZIM, NAGLAZYME, PALYNZIQ, GALAFOLD, BRINEURA, ALDURAZYME, POMBILITI and OPFOLDA, KUVAN and ROCTAVIAN. It completed its Amicus Acquisition on April 27, 2026.
The Third Quarter
Total revenues were USD 1.02 billion versus USD 776.1 million. Net product revenues were USD 1.01 billion versus USD 760.8 million, and Royalty and other revenues were USD 11.6 million versus USD 15.3 million. VOXZOGO net product revenues were USD 245.0 million versus USD 218.4 million.
Cost of sales was USD 205.4 million and research and development expense was USD 180.5 million. Acquired in-process research and development expense was USD 287.7 million versus USD 221.0 million. Selling, general and administrative expense was USD 333.6 million, intangible amortization was USD 99.5 million and total operating expenses were USD 1.11 billion.
The loss from operations was USD 82.1 million versus USD 46.7 million. Interest expense was USD 55.6 million versus USD 2.6 million, and the tax benefit was USD 8.9 million. The net loss was USD 122.8 million versus USD 30.7 million, or USD 0.63 per share versus USD 0.16.
Nine Months
Total revenues were USD 2.78 billion versus USD 2.35 billion. Net Income was USD 27.5 million versus USD 395.5 million, or USD 0.14 per diluted share versus USD 2.04. Income from operations was USD 158.5 million versus USD 454.1 million. Interest expense was USD 133.9 million versus USD 8.1 million, and the tax provision was USD 43.4 million versus USD 114.2 million.
Balance Sheet and Cash Flow
Cash and cash equivalents were USD 736.0 million versus USD 1.31 billion at December 31, 2025. Total Assets were USD 11.57 billion versus USD 7.59 billion, and total liabilities were USD 5.31 billion versus USD 1.51 billion. Total Debt was USD 4.24 billion versus USD 600.0 million. Operating Activities provided USD 577.0 million versus USD 728.4 million.
Deals and Regulatory Dates
On August 31 BioMarin completed its acquisition of Alesta Therapeutics for USD 303.4 million, with regulatory and sales milestones of up to USD 215 million. About USD 282.3 million of acquired in-process research and development expense for BMN 440 hit the third quarter.
In October it signed an exclusive worldwide license with GC Biopharma and Hanmi Pharm for BMN 450, an investigational enzyme replacement therapy for Fabry disease. It will pay USD 70.0 million upfront, expected to be booked as acquired in-process research and development expense in the fourth quarter. In November it announced that the FDA set a May 30, 2027 PDUFA target date for the VOXZOGO supplemental application in hypochondroplasia, and that the European Medicines Agency validated its submission.
2026 Guidance
On the November 2 call, management updated full-year revenue guidance to USD 3.8 billion to USD 3.9 billion. It said a single international customer indicated it intends to defer multiple expected orders totaling about USD 70 million. Non-GAAP Diluted Earnings per Share guidance was updated to USD 2.80 to USD 3.10.
What to Watch Next for BioMarin
The company has given no reason for the November 20 volume, and its results and guidance came earlier. The reported record shows higher revenue, a quarterly loss from acquisition charges, much higher debt and lower cash. The VOXZOGO review date and the Fabry license charge are the points to follow.






Please wait processing your request...